www.amgenmedinfo.com
866-572-6436
Amgen Oncology is testing the investigational drug tarlatamab (AMG 757) to see if it can help patients with either of two kinds of neuroendocrine cancer: small cell lung cancer (SCLC) or neuroendocrine prostate cancer (NEPC).
Move your cursor to either side of the page to learn more about tarlatamab clinical studies.
Underlined terms can be clicked for definition.
DeLLphi-304 (Phase 3) Clinical Study
A clinical study comparing tarlatamab with standard of care chemotherapy in patients whose cancer has returned after first-line treatment.
Click to Expand
DeLLpro-300 (Phase 1B) Clinical Study
A clinical study for patients with neuroendocrine prostate cancer (NEPC) that has spread to another site in the body after one previous treatment.
Click to Expand
How do I know if I have neuroendocrine prostate cancer?